Nothing Special   »   [go: up one dir, main page]

MX2013013436A - Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. - Google Patents

Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.

Info

Publication number
MX2013013436A
MX2013013436A MX2013013436A MX2013013436A MX2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A
Authority
MX
Mexico
Prior art keywords
treatment
indole derivatives
substituted indole
immunological disorders
substituted
Prior art date
Application number
MX2013013436A
Other languages
English (en)
Inventor
Nigel Graham Cooke
Rita Ramos
Karen Kammertoens
Maurice Van Eis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013013436A publication Critical patent/MX2013013436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a derivados de indol sustituidos, a procesos para su producción, a su uso como productos farmacéuticos, y a composiciones farmacéuticas que los comprenden. (I) (Ver Formula).
MX2013013436A 2011-05-17 2012-05-16 Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. MX2013013436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486808P 2011-05-17 2011-05-17
PCT/IB2012/052473 WO2012156936A1 (en) 2011-05-17 2012-05-16 Substituted indole derivatives for the treatment of immunological disorders

Publications (1)

Publication Number Publication Date
MX2013013436A true MX2013013436A (es) 2013-12-06

Family

ID=46210333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013436A MX2013013436A (es) 2011-05-17 2012-05-16 Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.

Country Status (15)

Country Link
US (2) US8703782B2 (es)
EP (1) EP2709998B1 (es)
JP (1) JP6043344B2 (es)
KR (1) KR20140023354A (es)
CN (1) CN103534250B (es)
AR (1) AR088414A1 (es)
AU (1) AU2012257345B2 (es)
BR (1) BR112013029416A2 (es)
CA (1) CA2835169C (es)
EA (1) EA023238B1 (es)
ES (1) ES2565200T3 (es)
MX (1) MX2013013436A (es)
TW (1) TW201249858A (es)
UY (1) UY34072A (es)
WO (1) WO2012156936A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
US20150284364A1 (en) * 2012-11-07 2015-10-08 Nicole Bieri Substituted indole derivatives
EP4005573A1 (en) * 2013-08-14 2022-06-01 Novartis AG Combination therapy for the treatment of cancer
EP3046560B1 (en) * 2013-09-18 2021-01-06 EpiAxis Therapeutics Pty Ltd Stem cell modulation ii
CN107106517A (zh) 2014-08-25 2017-08-29 堪培拉大学 用于调节癌干细胞的组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
HUP0203558A3 (en) 1999-10-12 2004-01-28 Hoffmann La Roche Substituted pyrroles as antiproliferative compounds for the treatment of cancer and pharmaceutical compositions containing them
ATE445613T1 (de) * 2000-11-07 2009-10-15 Novartis Pharma Gmbh Indolylmaleimidderivative als proteinkinase-c- inhibitoren
DE60231336D1 (de) 2001-12-21 2009-04-09 Guilford Pharm Inc Verfahren zur herstellung von wasserlöslichen phosphonooxymethyl-derivaten aus alkohol und phenol
CN1329036C (zh) 2001-12-28 2007-08-01 Mgigp公司 普鲁泊福水溶性前药的以水为基质的药物制剂
AR039209A1 (es) * 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
CA2480881C (en) 2002-04-08 2012-09-11 Guilford Pharmaceuticals, Inc. Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004083202A1 (en) 2003-03-19 2004-09-30 Suven Life Sciences Limited A process for the preparation of indolymaleimides
ES2337496T3 (es) 2005-01-19 2010-04-26 Rigel Pharmaceuticals, Inc. Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
WO2007008514A2 (en) 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
ATE540041T1 (de) 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
CN101812097B (zh) 2010-04-17 2012-04-25 中国海洋大学 吲哚咔唑和双吲哚马来酰亚胺生物碱及其制备方法和应用
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol

Also Published As

Publication number Publication date
JP2014518870A (ja) 2014-08-07
AR088414A1 (es) 2014-06-11
EP2709998A1 (en) 2014-03-26
BR112013029416A2 (pt) 2017-01-31
US9029396B2 (en) 2015-05-12
CA2835169C (en) 2019-05-14
US20130157980A1 (en) 2013-06-20
WO2012156936A1 (en) 2012-11-22
US8703782B2 (en) 2014-04-22
JP6043344B2 (ja) 2016-12-14
CA2835169A1 (en) 2012-11-22
TW201249858A (en) 2012-12-16
EA201391710A1 (ru) 2014-03-31
EP2709998B1 (en) 2016-01-06
UY34072A (es) 2013-01-03
AU2012257345B2 (en) 2016-03-24
ES2565200T3 (es) 2016-04-01
EA023238B1 (ru) 2016-05-31
CN103534250B (zh) 2016-05-11
CN103534250A (zh) 2014-01-22
US20140179634A1 (en) 2014-06-26
KR20140023354A (ko) 2014-02-26

Similar Documents

Publication Publication Date Title
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
IN2015KN00262A (es)
PH12016500094A1 (en) Autotaxin inhibitors
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MD20150091A2 (ro) Compuşi antivirali
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MY180165A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
TN2016000107A1 (en) Substituted phenylalanine derivatives
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2015DN00950A (es)
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX2015012350A (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4.
IN2015DN02660A (es)
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal